245469-58-3

Upstream product

• 103440-59-1 1-(4-hydroxy-3-iodo-5-methoxy-phenyl)ethan-1-one 
• 106-93-4 ethylene dibromide 
• 498-02-2 1-(3-methoxy-4-hydroxyphenyl)ethanone 

Downstream Products

• 245469-66-3 1-[3-methoxy-4-(4-chlorophenylthioethoxy)-5-iodophenyl]-4-(3,4,5-trimethoxyphenyl)butane-1,4-dione 
• 245469-67-4 1-[3-methoxy-4-(4-chlorophenylthioethoxy)-5-iodophenyl]-4-(3,4,5-trimethoxyphenyl)-1,4-butanediol 
• 193739-32-1 (+/-)-cis-2-[3-methoxy-4-(4-chlorophenylthioethoxy)-5-cyanophenyl]-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran 
• 245469-68-5 2-[3-methoxy-4-(4-chlorophenylthioethoxy)-5-iodophenyl]-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran 
• 245469-62-9 3-(N,N-dimethylamino)-1-[3-methoxy-4-(4-chlorophenylthioethoxy)-5-iodophenyl]propan-1-one 
• 245469-65-2 1-[3-methoxy-4-(4-chlorophenylthioethoxy)-5-iodophenyl]prop-2-en-1-one 
• 193739-32-1 (+/-)-trans-2-[3-methoxy-4-(4-chlorophenylthioethoxy)-5-cyanophenyl]-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran 
• 245469-59-4 ethanone-1-[3-methoxy-4-(4-chlorophenylthioethoxy)-5-iodophenyl] 

Relevant academic research and scientific papers

(±)-Trans-2-[3-methoxy-4-(4-chlorophenyl thioethoxy)-5-cyanophenyl]-5- (3,4,5-trimethoxyphenyl)tetrahydrofuran, a potent PAF-receptor antagonist

The synthesis of (±)-trans-2-[3-methoxy-4- (chlorophenylthioethoxyphenyl)-5-cyanophenyl]-5-(3,4,5- trimethoxyphenyl)tetrahydrofuran from commercially available acetovanillone and 3,4,5-trimethoxybenzaldehyde is described.

PHARMACEUTICAL FORMULATIONS USEFUL TO TREAT INFLAMMATORY AND IMMUNE DISORDERS

A pharmaceutical formulation is provided for the treatment of inflammatory and/or immune disorders, particularly those mediated by platelet activating factor (“PAF”) or a product of 5-lipoxygenase. The formulation, in one embodiment, is an essentially anhydrous ointment containing an active agent selected from the group consisting of 2,5-diaryl tetrahydrofurans, 2,5-diaryl tetrahydrothiophenes, 2,4-diaryl tetrahydrofurans, 2,4-diaryl tetrahydrothiophenes, 1,3-diaryl cyclopentanes, 2,4-diaryl pyrrolidines, and 2,5-diaryl pyrrolidines, and an enhancer composition containing one or more C3-18 esters such as diethyl succinate, propylene carbonate, diisopropyl adipate and glyceryl triacetate. In another embodiment, the formulation is a cream, gel, lotion, oil, or the like, containing the: active agent in crystalline form. The invention also encompasses the novel crystalline form of the active agent, and methods for using the formulations to treat individuals with inflammatory and/or immune disorders. Also encompassed is use of isopropyl alcohol (IPA) to enhance stability of the active agent and pharmaceutical formulations.

Synthesis and antimicrobial activity of 1-[3-methoxy-4-[4-chlorophenylthioethoxy]-5-iodophenyl]prop-2-ene-1-one and its intermediates

The synthesis and antimicrobial activity of 1-[3-methoxy-4-(4-chlorophenylthioethoxy)-5-iodophenyl]prop-2-ene-1-one, which is used as an important intermediate for the synthesis of 2.5-transdiaryltetrahydronfuran, are reported.

Method for synthesizing diaryl-substituted heterocyclic compounds, including tetrahydrofurans

A method is provided for synthesizing diaryl-substituted heterocyclic compounds, particularly 2,5-diaryl-substituted tetrahydrofurans and tetrahydrothiophenes. Methods for synthesizing starting materials and intermediates are provided as well. An importan